LillyDirect (Zepbound) vs MEDVi (2026): prices, structure, verdict

On tirzepatide, MEDVi↗ is cheaper: $399 versus $449 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing, and MEDVi's figure is dose-flat while LillyDirect (Zepbound)↗'s structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only MEDVi has a rankable figure: $299 a month all-in; LillyDirect (Zepbound) does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

LillyDirect (Zepbound): the record, condensed

Start with the load-bearing figure: $449 a month, all-in, is what LillyDirect (Zepbound) charges for tirzepatide at the 10 mg basis. The structure is tiered: the advertised entry point is $299, but the maintenance figure — the one a full year is actually billed at — is $449. That $150 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $449 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #0 of 17 verified programs, with the floor $234/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $5,388 monthly-billed.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: MEDVi at $399, LillyDirect (Zepbound) at $449 — a $50 monthly spread that compounds to $600 over a maintenance year and $1,200 over two.

Structure sharpens the gap: MEDVi’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while LillyDirect (Zepbound)’s is not — so MEDVi’s number is a ceiling and LillyDirect (Zepbound)’s advertised entry ($299) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

A way to feel the $50 monthly gap: over a year it funds 1.5 extra months at MEDVi’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $1,200, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: LillyDirect (Zepbound) $449/mo month-to-month against MEDVi $399/mo month-to-month. The order holds: MEDVi leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: LillyDirect (Zepbound) $1,347 monthly; MEDVi $1,197 monthly — best path favors MEDVi by $150. 6 months: LillyDirect (Zepbound) $2,694 monthly; MEDVi $2,394 monthly — best path favors MEDVi by $300. 12 months: LillyDirect (Zepbound) $5,388 monthly; MEDVi $4,788 monthly — best path favors MEDVi by $600. 24 months: LillyDirect (Zepbound) $10,776 monthly; MEDVi $9,576 monthly — best path favors MEDVi by $1,200.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: LillyDirect (Zepbound) publishes “50 states”; MEDVi publishes “priced differently in CA/NC on some plans” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); MEDVi does not, which shifts the burden of verification onto your intake questions.

Exit terms: LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply. MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

Evidence: LillyDirect (Zepbound) source-verified (captured 2026-08-09); MEDVi source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

§ If you move

Switching between LillyDirect (Zepbound) and MEDVi

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (LillyDirect (Zepbound): no subscription; refill-window rules apply; MEDVi: 12-month plan applies to lowest rate) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings